![中国临床肿瘤学会(CSCO)恶性血液病诊疗指南·2020](https://wfqqreader-1252317822.image.myqcloud.com/cover/547/33145547/b_33145547.jpg)
上QQ阅读APP看书,第一时间看更新
2.5 治疗
2.5.1 诱导缓解治疗
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image141.jpg?sign=1739014703-YzWV0JrfFNaD4L3bwSqrXdYKA5xJHii3-0-adb12d0e92cbf36bec779770a55befcd)
所有急性髓系白血病患者,可以参加临床研究的情况下,均建议首选参加临床研究。在没有临床研究的情况下,可以参照下述建议进行治疗。本章节为年龄<60岁成人患者。
2.5.2 诱导治疗后检测
诱导治疗过程中,建议在骨髓抑制期(停化疗后第7~14天左右)、恢复期(停化疗后第21~28天左右)复查骨髓。根据骨髓抑制期、血象恢复期的骨髓情况进行治疗调整。
(1)标准剂量Ara-C诱导后治疗监测
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image142.jpg?sign=1739014703-0zfP91YXX9dpFH1OpS30OjE8uKK0cU4a-0-0826abdb726159e6172b7f8a03939f5d)
标准剂量Ara-C诱导后治疗监测(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image143.jpg?sign=1739014703-yUOx5J0woc5KnmDhjDTZT57oNq1fB7KE-0-22886805d9e6a552537b1cfe3caa820d)
标准剂量Ara-C诱导后治疗监测(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image144.jpg?sign=1739014703-cuVMzQiskkoFFRgqvsplmlMML6c2vpqB-0-d104bec357d7c51eb7dfe830585624d5)
(2)含中大剂量Ara-C方案的诱导后治疗监测
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image145.jpg?sign=1739014703-e4YzEtoTIGyc3nDjZi0r9LK2iUSV0v8y-0-0e127a6b85628c7d431d931b39c0a12e)
2.5.3 AML完全缓解后治疗的选择
按遗传学预后危险度分组治疗
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image146.jpg?sign=1739014703-s8ljSuM5lg1CU2aGxGDvaRpiZSJiHoVq-0-ffcf5ce68aa5f2bda4749b62aa017ccc)
按遗传学预后危险度分组治疗(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image147.jpg?sign=1739014703-CSV37e2zIXijflBbc6rJ19mwJW22Wiry-0-4cba402aa7980f9102cfc3aaebcfba61)
按遗传学预后危险度分组治疗(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image148.jpg?sign=1739014703-8Bb8uooZU4BGQT4dRGI77be2ZwF2jTdQ-0-f81d15afc1855162eea48c9a6983c47e)